impactmf: imetelstat vs best available therapy in patients with myelofibrosis
Published 2 years ago • 987 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
1:59
phase iii trial of imetelstat versus best available therapy in refractory mf
-
1:40
the role of imetelstat in the treatment of myelofibrosis and insights into the impactmf study
-
3:08
htert reduction by imetelstat correlates with clinical activity in mds
-
3:35
new phase iii trial of imetelstat versus bat in jak inhibitor-refractory myelofibrosis
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
21:52
pv pod: stories from the marrow, episode 1: polycythemia vera 101
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
17:18
【mhc tetramer】a powerful tool for monitoring immune cells in diseases
-
1:44
an update on imetelstat in r/r myelofibrosis
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
1:24
imetelstat in high-risk triple-negative myelofibrosis
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
2:05
does imetelstat increase the need for platelet transfusions & growth factors in pts with lr-mds?
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
2:00
imetelstat in heavily-transfused lower-risk r/r mds
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
3:50
imetelstat efficacy is independent of molecular subtypes in r/r lr-mds
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial